NPS is considering to abandon osteoporosis indication in Europe which generated north of $80 million revenue in 2011 to persue an orphan indication, hypoparathyroidism. Is any other example in pharmaceutical industry for a company that stop selling a drug for a major disease in order to switch to an orphan condition?
Don't know the answer to your question but I read that NPS hired Sandy Smith ,former president of Genzymes's international unit, as a commercialization consultant focused on international expansion . So
sounds like they have a good person leading the charge. Sure is a interesting and exciting move today.
Good days ahead and good luck to you.